Æterna Terminates Agreement With Sanofi-aventis US
Æterna Zentaris has terminated its agreement with Sanofi-aventis US signed on March 5, 2009 for the development, commercialisation and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.